Adzenys Xr-Odt

Narcolepsy, Depression, Attention Deficit Hyperactivity Disorder + 1 more

Treatment

2 FDA approvals

20 Active Studies for Adzenys Xr-Odt

What is Adzenys Xr-Odt

Amphetamine/Dextroamphetamine

The Generic name of this drug

Treatment Summary

Amphetamine is a controlled drug used for specific medical conditions. It was discovered in 1910 and first synthesized by 1927. In 1935, it was approved by Smith, Kline and French for treatment of drug-induced anesthesia, arousal, and insomnia. During World War II, amphetamine was used to keep soldiers alert, which led to an overproduction of the drug and an increase in black market sale. In 1976, it was approved by the FDA.

Adderall

is the brand name

image of different drug pills on a surface

Adzenys Xr-Odt Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Adderall

Amphetamine/Dextroamphetamine

1996

507

Approved as Treatment by the FDA

Amphetamine/Dextroamphetamine, also known as Adderall, is approved by the FDA for 2 uses such as Narcolepsy and Attention Deficit Hyperactivity Disorder .

Narcolepsy

Attention Deficit Hyperactivity Disorder

Used to treat Attention Deficit Hyperactivity Disorder (ADHD) in combination with Dextroamphetamine

Effectiveness

How Adzenys Xr-Odt Affects Patients

Amphetamine increases the levels of two key brain chemicals - noradrenaline in the prefrontal cortex and dopamine in the striatum - in a dose and time-dependent manner. This has been linked to improved school performance, behavior, and demeanor in ADHD patients. While amphetamine has been linked to cognitive enhancement, it can also lead to psychiatric dangers such as paranoia when misused. It can also worsen depression and anxiety.

How Adzenys Xr-Odt works in the body

Amphetamine has a similar structure to the catecholamine neurotransmitters, which makes it easy for it to be taken up by the presynaptic nerve terminals. Once inside the terminal, it is stored by a protein called VMAT2 and is then released into the synapse. Amphetamine also increases monoamine concentration by preventing its reuptake and inhibiting an enzyme called MAO that breaks down neurotransmitters. The l-isomer of amphetamine is less potent than the d-isomer when it comes to releasing dopamine.

When to interrupt dosage

The measure of Adzenys Xr-Odt is contingent upon the diagnosed illness, including Disease, Chronic Pain and Attention Deficit Hyperactivity Disorder. The amount additionally diverges as per the method of delivery (e.g. Oral or Tablet - Oral) noted in the table hereunder.

Condition

Dosage

Administration

Attention Deficit Hyperactivity Disorder

, 5.0 mg, 10.0 mg, 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg, 2.5 mg/mL, 3.125 mg, 9.375 mg, 6.25 mg, 1.875 mg, 2.5 mg, 7.5 mg, 1.25 mg, 3.75 mg, 15.0 mg, 1.25 mg/mL, 18.75 mg, 25.0 mg, 7.26 mg, 12.11 mg, 2.42 mg, 9.69 mg, 14.53 mg, 4.84 mg, 20.0 mg, 60.0 mg, 40.0 mg, 30.0 mg

, Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Suspension, extended release - Oral, Suspension, extended release, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral

Chronic Pain

, 5.0 mg, 10.0 mg, 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg, 2.5 mg/mL, 3.125 mg, 9.375 mg, 6.25 mg, 1.875 mg, 2.5 mg, 7.5 mg, 1.25 mg, 3.75 mg, 15.0 mg, 1.25 mg/mL, 18.75 mg, 25.0 mg, 7.26 mg, 12.11 mg, 2.42 mg, 9.69 mg, 14.53 mg, 4.84 mg, 20.0 mg, 60.0 mg, 40.0 mg, 30.0 mg

, Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Suspension, extended release - Oral, Suspension, extended release, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral

Narcolepsy

, 5.0 mg, 10.0 mg, 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg, 2.5 mg/mL, 3.125 mg, 9.375 mg, 6.25 mg, 1.875 mg, 2.5 mg, 7.5 mg, 1.25 mg, 3.75 mg, 15.0 mg, 1.25 mg/mL, 18.75 mg, 25.0 mg, 7.26 mg, 12.11 mg, 2.42 mg, 9.69 mg, 14.53 mg, 4.84 mg, 20.0 mg, 60.0 mg, 40.0 mg, 30.0 mg

, Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Suspension, extended release - Oral, Suspension, extended release, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral

Depression

, 5.0 mg, 10.0 mg, 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg, 2.5 mg/mL, 3.125 mg, 9.375 mg, 6.25 mg, 1.875 mg, 2.5 mg, 7.5 mg, 1.25 mg, 3.75 mg, 15.0 mg, 1.25 mg/mL, 18.75 mg, 25.0 mg, 7.26 mg, 12.11 mg, 2.42 mg, 9.69 mg, 14.53 mg, 4.84 mg, 20.0 mg, 60.0 mg, 40.0 mg, 30.0 mg

, Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Suspension, extended release - Oral, Suspension, extended release, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral

Warnings

Adzenys Xr-Odt Contraindications

Condition

Risk Level

Notes

Agitation

Do Not Combine

advanced arteriosclerosis

Do Not Combine

Drug abuse

Do Not Combine

Hyperthyroidism

Do Not Combine

Hypertensive disease

Do Not Combine

symptomatic cardiovascular disease

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Amphetamine/Dextroamphetamine may interact with Pulse Frequency

There are 20 known major drug interactions with Adzenys Xr-Odt.

Common Adzenys Xr-Odt Drug Interactions

Drug Name

Risk Level

Description

Clonidine

Major

The metabolism of Clonidine can be decreased when combined with Amphetamine.

Cyclophosphamide

Major

The metabolism of Cyclophosphamide can be decreased when combined with Amphetamine.

Dacomitinib

Major

The metabolism of Dacomitinib can be decreased when combined with Amphetamine.

Enasidenib

Major

The metabolism of Enasidenib can be decreased when combined with Amphetamine.

Erlotinib

Major

The metabolism of Erlotinib can be decreased when combined with Amphetamine.

Adzenys Xr-Odt Toxicity & Overdose Risk

The typical fatal dose of amphetamine is 6.4 mg/l. An overdose on amphetamine can lead to high body temperature, difficulty breathing, seizures, acidosis, kidney failure, liver damage, and coma. Neurological effects include confusion, aggression, irritability, headaches, and hallucinations. Cardiovascular effects include irregular heartbeats, heart muscle damage, heart attack, and stroke. Gastrointestinal effects include abdominal pain, vomiting, diarrhea, cramps, loss of appetite, and bleeding. Animal studies have not found amphetamine to cause cancer, chromosomal damage, or fertility issues.

image of a doctor in a lab doing drug, clinical research

Adzenys Xr-Odt Novel Uses: Which Conditions Have a Clinical Trial Featuring Adzenys Xr-Odt?

Presently, there are 710 active studies investigating the possibility of Adzenys Xr-Odt to serve as a therapeutic intervention for Depression, Disease and Narcolepsy.

Condition

Clinical Trials

Trial Phases

Narcolepsy

2 Actively Recruiting

Not Applicable, Phase 1

Attention Deficit Hyperactivity Disorder

63 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2

Chronic Pain

0 Actively Recruiting

Depression

305 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Adzenys Xr-Odt Reviews: What are patients saying about Adzenys Xr-Odt?

5

Patient Review

5/3/2018

Adzenys Xr-Odt for Attention Deficit Disorder with Hyperactivity

I was amazed at how well this worked for my daughter! It was a real life-changer, but unfortunately we can't keep up with the costs.

5

Patient Review

3/19/2019

Adzenys Xr-Odt for Attention Deficit Disorder with Hyperactivity

I've never felt better taking a medication! Adzenys is so natural feeling-- no initial bump and no let down in the evenings. The only side effect I experienced was dry mouth. No problems with blood pressure or sleep, even though my blood pressure is controlled by medication. This drug helped me to be more focused, alert, and productive.

5

Patient Review

9/22/2016

Adzenys Xr-Odt for Attention Deficit Disorder with Hyperactivity

5

Patient Review

11/10/2016

Adzenys Xr-Odt for Attention Deficit Disorder with Hyperactivity

We switched my son to this treatment from Concerta and so far it's going well! We've found that it only lasts for about 8 hours, but there isn't the crash at the end of the day and he's been sleeping soundly through the night.

4.7

Patient Review

5/4/2021

Adzenys Xr-Odt for Attention Deficit Disorder with Hyperactivity

We made the switch to this treatment from Eveekeo when we were seeking an extended release medication for my son that he wouldn't have to take during school hours. We couldn't be happier. It lasts around seven to eight hours with no hard crash and no issues falling asleep at night. Very satisfied.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about adzenys xr-odt

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long does Adzenys XR-ODT last?

"Adzenys XR-ODT is a tablet that is designed to dissolve in your mouth instead of being swallowed. It has an effect that lasts for 10 to 12 hours."

Answered by AI

Is Adzenys XR-ODT the same as Adderall?

"Adzenys XR-ODT is the first FDA-approved extended-release orally disintegrating amphetamine tablet. It is bioequivalent to Adderall XR, but is not a generic of it."

Answered by AI

What is Adzenys XR-ODT used for?

"This medication is used to treat attention deficit hyperactivity disorder - ADHD. It works by altering the levels of certain natural substances in the brain. Amphetamine is a type of drug classified as a stimulant."

Answered by AI

How long does Adzenys XR-ODT take to kick in?

"The main difference between Adzenys XR-ODT and other medications is that Adzenys XR-ODT starts working within an hour, while other medications work instantly. Adzenys XR-ODT also lasts up to 12 hours, while other medications only last for a few hours."

Answered by AI

Clinical Trials for Adzenys Xr-Odt

Image of The Korean Association of West Florida in Tampa, United States.

Mobile App Mindfulness for Mental Health

18+
All Sexes
Tampa, FL

The goal of this clinical trial (single-arm pilot trial) is to learn whether a mobile application-based mindfulness intervention can improve mental health outcomes in older Korean immigrants aged 60 years and older. The main questions it aims to answer are whether the 8-week mobile app-based mindfulness intervention is feasible and acceptable, as indicated by recruitment, retention, and adherence rates, and whether participation in the intervention leads to improvements in positive psychological well-being (e.g., positive affect, optimism, life engagement, and mindfulness) and reductions in adverse mental health outcomes (e.g., anxiety, depressive symptoms, and perceived stress). Participants will complete baseline and post-intervention assessments, receive training on how to use the mobile mindfulness application, engage with the app for approximately 8 weeks (recommended 10-15 minutes per day), and participate in weekly check-ins to support engagement and address any challenges encountered during the intervention.

Waitlist Available
Has No Placebo

The Korean Association of West Florida (+1 Sites)

Soonhyung Kwon

Image of Brown University in Providence, United States.

Mindfulness-Based Intervention for Mental Health

18 - 24
All Sexes
Providence, RI

The goal of this clinical trial (single-arm feasibility study) is to examine the feasibility, acceptability, and preliminary efficacy of a mindfulness-based, app-delivered intervention to address mental health and emotion regulation challenges in young adults with early life adversities (ELAs). The main questions it aims to answer is: \- Will young adults find the Growth, Empowerment, and Mindfulness (GEM) intervention to be both feasible and acceptable, as demonstrated by participants' engagement and quantitative/qualitative feedback? Additionally, it aims to answer: * Will GEM intervention demonstrate preliminary efficacy in improving outcome measures including depression, anxiety? * Are improvements in mindfulness and sleep, as well as reductions in rumination, mechanisms of action underlying the improvements in psychological and behavioral outcomes of the intervention? Participants will be asked to: * participate in GEM, which integrates app-based intervention content, formal and informal mindfulness practices, weekly Zoom group sessions, and ecological momentary intervention (EMI) delivery * complete baseline, post-intervention, and 3-month follow-up assessments * complete weekly assessments and daily ecological momentary assessments (EMAs) during the intervention delivery * wear Fitbit for researchers to collect sleep-related data

Recruiting
Has No Placebo

Brown University

Shufang Sun, PhD

Image of Michael E. DeBakey VA Medical Center, Houston, TX in Houston, United States.

Behavioral Activation-Guided Self-Help for Depression

18+
All Sexes
Houston, TX

Symptoms of depression are highly prevalent among Veterans. However, fewer than 30% of individuals with these symptoms receive any psychotherapy in the Veterans Health Administration (VHA). This is due to many factors, which may include provider availability and patient preferences. Guided self-help (GSH), which involves coaching sessions with patients who are following a fully developed self-help program, has the potential to increase access to care for these Veterans, particularly if implemented within a stepped care model of mental health treatment delivery and if delivered by a diverse set of providers. The VHA's primary care-mental health integration (PCMHI) service, which focuses on short courses of care for mild to moderate symptoms, may be an ideal place in which to deploy GSH. The current project seeks conduct a pilot randomized trial of a GSH program for depression adapted for PCMHI based on behavioral activation.

Waitlist Available
Has No Placebo

Michael E. DeBakey VA Medical Center, Houston, TX

Maribel Plasencia, BA MS PhD

Have you considered Adzenys Xr-Odt clinical trials?

We made a collection of clinical trials featuring Adzenys Xr-Odt, we think they might fit your search criteria.
Go to Trials
Image of UC San Diego Health Psychiatry in San Diego, United States.

Medi-TBS for Depression

18 - 65
All Sexes
San Diego, CA

Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of \~30%. Additionally, rTMS has not been shown to improve cognitive functioning that may be an independent factor predicting treatment success. This study will develop a novel multimodal treatment, which combines intermittent theta burst stimulation (iTBS) - a type of rTMS with digital mindfulness training to engage brain plasticity, enhance cognition and alleviate depression symptoms in individuals with TRD.

Phase 2
Recruiting

UC San Diego Health Psychiatry

Image of UF World Equestrian Center in Ocala, United States.

ONE-D TMS + D-Cycloserine for Depression and Concussion

18 - 65
Female
Ocala, FL

Concussion and depression have long been recognized to be intertwined pathologies.1-3 Although female athletes are more likely to suffer from mental health symptoms than males athletes following a concussion,2 research in this area has been largely biased toward males.4 Recently functional MRI (fMRI) studies5 in concussed athletes have established that there are patterns of local alterations in neural connectivity in the frontal cortex that demonstrate anatomic congruency with transcranial magnetic stimulation (TMS) studies that mapped alternations in neural connectivity to functional and somatic symptoms.6 Thus, there is potential that TMS treatment could decrease both symptom profiles, revolutionizing comorbid treatment options. Possible Benefits: Previous studies have showed a 70% remission rate for depression symptoms. It is possible that participants could have improvement in depressive or concussive symptoms after the ONE-D TMS treatment.

Phase 2 & 3
Waitlist Available

UF World Equestrian Center

Sara Gould, MD

Image of CVT in Centennial, United States.

Treatment for Anxiety Disorders

18 - 70
All Sexes
Centennial, CO

The goal of this hybrid implementation-effectiveness study is to learn about the effectiveness and appropriateness of "Trauma-Informed and Culturally-Responsive Integrated Massage Therapy" (TCI-Massage) for torture and war trauma survivors. The study aims are: • Examine the uptake of TCI-Massage within CVT by assessing key implementation science outcomes of acceptability and appropriateness among refugees and asylum seekers from diverse cultural backgrounds. • Examine the integration of massage therapy into the current psychosocial care model used at CVT. • Examine the effectiveness of TCI-Massage for torture and war trauma survivors to reduce distress (mental health symptoms, chronic pain, and HRV) and improve coping (interoceptive awareness and social functioning). Treatment group participants will participate in psychosocial care services + TCI-Massage, which the control group will only participate in psychosocial care services

Waitlist Available
Has No Placebo

CVT

Have you considered Adzenys Xr-Odt clinical trials?

We made a collection of clinical trials featuring Adzenys Xr-Odt, we think they might fit your search criteria.
Go to Trials
Image of Northwestern University in Chicago, United States.

Mothers and Babies Program for Depression in Parents of Children With Down Syndrome

18+
All Sexes
Chicago, IL

Goal: This R34 study will pilot an adaptation for the Mothers and Babies (MB) program for expectant and new parents of infants with Down syndrome (MBDS). Background: Expectant and new parents of infants with Down syndrome are at high risk for perinatal depression. Perinatal depression is both independently, and exponentially associated with long-term adverse neurodevelopmental consequences for infants with Down syndrome. MB is a cognitive-behavioral intervention designed to prevent perinatal depression. MB as one of the two most effective counseling interventions for perinatal depression prevention, with moderate to large effects sizes found across a series of randomized controlled trials (RCTs). However, research suggests that expectant and new parents of children with Down syndrome may have needs that standard MB does not address. Significance: This project will pilot a Down syndrome adaptation to MB, MBDS designed to target mechanisms of grief/loss and social support; and assess whether changes in the target mechanisms are associated with changes in depressive symptoms and parental sensitivity and responsivity to the infant. Innovation: The proposed project is innovative in three ways. First, the investigators plan to conduct the first pilot of a perinatal depression prevention intervention specifically designed for expectant and new parents of infants with Down syndrome. Second, the investigators plan to include fathers, nonbinary, and transgender parents to target symptoms of depression, rather than as simply a support person for maternal depressive symptom reduction. Third, the investigators plan to use a group format to establish cohorts of families of infants with Down syndrome of similar developmental stages. Design: Human-centered design and an open trial will inform a subsequent small randomized controlled clinical pilot to test the feasibility of the study protocol in preparation for a larger randomized controlled trial (RCT). Population: New and expectant parents of infants with Down syndrome. Outcomes: All aspects of the study protocol (e.g., condition allocation, treatment and control condition procedures, data collection, etc.) will be operationalized in preparation for the subsequent RCT. The investigators will assess MBDS effectiveness on target mechanisms of grief/loss and social support; and assess whether changes in the target mechanisms are associated with changes in depressive symptoms and parental sensitivity and responsivity to the infant.

Waitlist Available
Has No Placebo

Northwestern University

Heather J Risser

Image of Providence VA Medical Center, Providence, RI in Providence, United States.

Intermittent Theta-Burst Stimulation for ADHD

18 - 65
All Sexes
Providence, RI

Impaired inhibitory response manifests clinically as increased impulsivity, which leads to poorer affective, cognitive, social, and occupational functioning. Neuropsychiatric disorders prevalent among Veterans, such as Attention Deficit/Hyperactivity Disorder (ADHD), are associated with poor inhibitory control. The mainstay of clinical treatment for ADHD is psychostimulants, yet these medications have significant risks, including dependence and numerous side effects. Thus, novel and non-pharmacological therapeutic strategies are needed. Intermittent Theta Burst Stimulation, a newer form of transcranial magnetic stimulation, has emerged as a promising tool for modulating inhibitory neuronal circuits. This research proposal will investigate the feasibility and acceptability of iTBS on inhibitory control and impulsivity through a randomized controlled trial to inform clinical observations. The long-term goal is to improve impulsivity, social and occupational functioning, and enhance the quality of life for Veterans.

Waitlist Available
New This Month

Providence VA Medical Center, Providence, RI

Camila Souza A Cosmo, PhD

Image of San Diego State University in San Diego, United States.

Sleep Health Program for Marines

18+
All Sexes
San Diego, CA

The goal of this study is to test a sleep health program designed specifically for U.S. Marine Corps personnel. Researchers want to determine if this program helps Marines improve the participants sleep quality and overall mental health. The study will evaluate whether the program improves sleep quality and duration and reduces symptoms of depression, anxiety, PTSD, and suicide ideation. There are three distinct sleep health programs that will be evaluated; participants will be randomly assigned to one of five groups to receive different combinations of the sleep health programs. To measure results, researchers will use participant surveys for all enrolled participants and wearable sleep-tracking devices for a sub-set of participants. The study team expects that Marines who receive the most comprehensive version of the program will show the greatest improvements in sleep and psychological well-being.

Phase 2
Recruiting

San Diego State University

Emily Schmied, PhD

Image of University of Michigan in Ann Arbor, United States.

Virtual Reality for Depression in Multiple Sclerosis

18+
All Sexes
Ann Arbor, MI

This trial explores the use of immersive virtual reality (VR) nature-based experiences as a supplementary treatment for depression in individuals with progressive multiple sclerosis (MS). This study will evaluate the feasibility and efficacy of at-home VR deployment using the Apple Vision Pro, an advanced device that offers enhanced resolution, immersion, and usability compared to earlier VR systems. The study hypotheses include: * The integration of VR nature-based experiences with standard care will be feasible, acceptable, and will result in greater reductions in depressive symptoms compared to standard care or VR-only interventions. * The integration of VR nature-based experiences with standard care will result in greater reductions in stress and anxiety, better sleep, less insomnia, and improved fatigue compared to standard care alone or VR-only interventions.

Recruiting
Has No Placebo

University of Michigan

Hala Darwish, PhD

Apple Inc.

Have you considered Adzenys Xr-Odt clinical trials?

We made a collection of clinical trials featuring Adzenys Xr-Odt, we think they might fit your search criteria.
Go to Trials